160 related articles for article (PubMed ID: 32304367)
1. Evaluation of 5-hydroxyindoloacetic acid excretion in urine in patients with small intestine neuroendocrine neoplasm and carcinoid syndrome treated with somatostatin analogues.
Gut P; Ruchała M
Neuro Endocrinol Lett; 2019 Dec; 40(7-8):315-318. PubMed ID: 32304367
[TBL] [Abstract][Full Text] [Related]
2. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues.
Gut P; Czarnywojtek A; Ruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1319-1324. PubMed ID: 33269818
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin Analogues in Neuroendocrine Tumors.
Kulke MH
J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
[No Abstract] [Full Text] [Related]
6. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
7. The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.
Eriksson B; Janson ET; Bax ND; Mignon M; Morant R; Opolon P; Rougier P; Oberg KE
Digestion; 1996; 57 Suppl 1():77-80. PubMed ID: 8813476
[TBL] [Abstract][Full Text] [Related]
8. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
9. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
Jacobsen MB; Hanssen LE
J Intern Med; 1995 Mar; 237(3):269-75. PubMed ID: 7534331
[TBL] [Abstract][Full Text] [Related]
10. Carcinoid tumors--somatostatine in the diagnosis and therapy.
Kinova S; Duris I; Kratochvilova E; Ondrejka P; Payer J
Bratisl Lek Listy; 2002; 103(3):108-12. PubMed ID: 12190042
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.
Wängberg B; Westberg G; Tylén U; Tisell L; Jansson S; Nilsson O; Johansson V; Scherstén T; Ahlman H
World J Surg; 1996 Sep; 20(7):892-9; discussion 899. PubMed ID: 8678968
[TBL] [Abstract][Full Text] [Related]
12. [Urinary 5-HIAA stimulation test for the diagnosis of carcinoid syndrome caused by carcinoid tumors of the middle intestine].
Varas MJ; Navarro MA; Rosell P; García F
Rev Esp Enferm Apar Dig; 1986 Oct; 70(4):311-5. PubMed ID: 2431444
[No Abstract] [Full Text] [Related]
13. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
14. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogues do not prevent carcinoid crisis.
Guo LJ; Tang CW
Asian Pac J Cancer Prev; 2014; 15(16):6679-83. PubMed ID: 25169508
[TBL] [Abstract][Full Text] [Related]
16. Treatment of the carcinoid syndrome by hemihepatectomy and radical excision of the primary lesion.
Gillett DJ; Smith RC
Am J Surg; 1974 Jul; 128(1):95-9. PubMed ID: 4276000
[No Abstract] [Full Text] [Related]
17. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors.
Gregersen T; Grønbæk H; Worsøe J; Schlageter V; Laurberg S; Krogh K
Scand J Gastroenterol; 2011 Jul; 46(7-8):895-902. PubMed ID: 21623673
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogue phase I trials in neuroendocrine neoplasms.
Anthony L; Johnson D; Hande K; Shaff M; Winn S; Krozely M; Oates J
Acta Oncol; 1993; 32(2):217-23. PubMed ID: 7686764
[TBL] [Abstract][Full Text] [Related]
19. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.
Tirosh A; Nilubol N; Patel D; Kebebew E
Endocr Pract; 2018 Aug; 24(8):710-717. PubMed ID: 30084688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]